Targeting transcription factor corepressors in tumor cells

[1]  G. Jenster,et al.  Androgen receptor coregulators: Recruitment via the coactivator binding groove , 2012, Molecular and Cellular Endocrinology.

[2]  J. Schwabe,et al.  Nuclear hormone receptor co-repressors: Structure and function , 2012, Molecular and Cellular Endocrinology.

[3]  Tian-Li Wang,et al.  ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. , 2011, Cancer research.

[4]  D. Welch,et al.  Unraveling the enigmatic complexities of BRMS1‐mediated metastasis suppression , 2011, FEBS letters.

[5]  Peter A. Jones,et al.  A decade of exploring the cancer epigenome — biological and translational implications , 2011, Nature Reviews Cancer.

[6]  A. Papavassiliou,et al.  Tackling transcription factors: challenges in antitumor therapy. , 2011, Trends in molecular medicine.

[7]  L. D. Croce,et al.  Roles of the Polycomb group proteins in stem cells and cancer , 2011, Cell Death and Disease.

[8]  H. Mukhtar,et al.  Ligand-dependent Corepressor Acts as a Novel Androgen Receptor Corepressor, Inhibits Prostate Cancer Growth, and Is Functionally Inactivated by the Src Protein Kinase* , 2011, The Journal of Biological Chemistry.

[9]  J. M. Barrett,et al.  Corepressor effect on androgen receptor activity varies with the length of the CAG encoded polyglutamine repeat and is dependent on receptor/corepressor ratio in prostate cancer cells , 2011, Molecular and Cellular Endocrinology.

[10]  P. Wade,et al.  Cancer biology and NuRD: a multifaceted chromatin remodelling complex , 2011, Nature Reviews Cancer.

[11]  C. Roberts,et al.  SWI/SNF nucleosome remodellers and cancer , 2011, Nature Reviews Cancer.

[12]  J. Céraline,et al.  A designed cell-permeable aptamer-based corepressor peptide is highly specific for the androgen receptor and inhibits prostate cancer cell growth in a vector-free mode. , 2011, Endocrinology.

[13]  P. Yin,et al.  Retinoic acid inhibits endometrial cancer cell growth via multiple genomic mechanisms. , 2011, Journal of molecular endocrinology.

[14]  R. Vadlamudi,et al.  Epigenetics of Estrogen Receptor Signaling: Role in Hormonal Cancer Progression and Therapy , 2011, Cancers.

[15]  G. Crabtree,et al.  ATP-dependent chromatin remodeling: genetics, genomics and mechanisms , 2011, Cell Research.

[16]  P. Grandi,et al.  Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes , 2011, Nature Biotechnology.

[17]  G. Reifenberger,et al.  Expression of nuclear receptor corepressors and class I histone deacetylases in astrocytic gliomas , 2011, Cancer science.

[18]  C. Deng,et al.  Redox-dependent Brca1 transcriptional regulation by an NADH-sensor CtBP1 , 2010, Oncogene.

[19]  M. Goodson,et al.  Nuclear receptor coregulators as a new paradigm for therapeutic targeting. , 2010, Advanced drug delivery reviews.

[20]  Richard A. Moore,et al.  ARID1A mutations in endometriosis-associated ovarian carcinomas. , 2010, The New England journal of medicine.

[21]  S. Ellison-Zelski,et al.  Maximum growth and survival of estrogen receptor-alpha positive breast cancer cells requires the Sin3A transcriptional repressor , 2010, Molecular Cancer.

[22]  C. Schiffer,et al.  Therapeutic targeting of C-terminal binding protein in human cancer , 2010, Cell cycle.

[23]  G. Chinnadurai,et al.  Incapacitating CtBP to kill cancer , 2010, Cell cycle.

[24]  Li M. Li,et al.  Transcriptional Repression: Conserved and Evolved Features , 2010, Current Biology.

[25]  C. Cooper,et al.  Elevated NCOR1 disrupts PPARalpha/gamma signaling in prostate cancer and forms a targetable epigenetic lesion. , 2010, Carcinogenesis.

[26]  H. Brauch,et al.  Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulation , 2010, Proceedings of the National Academy of Sciences.

[27]  A. Zelent,et al.  Interference with Sin3 function induces epigenetic reprogramming and differentiation in breast cancer cells , 2010, Proceedings of the National Academy of Sciences.

[28]  M. Campbell,et al.  Transcription factor co‐repressors in cancer biology: roles and targeting , 2010, International journal of cancer.

[29]  Linfeng Chen,et al.  Inhibition of MAP kinase promotes the recruitment of corepressor SMRT by tamoxifen-bound estrogen receptor alpha and potentiates tamoxifen action in MCF-7 cells. , 2010, Biochemical and biophysical research communications.

[30]  Alexander D. MacKerell,et al.  A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. , 2010, Cancer cell.

[31]  Li Kai,et al.  Resveratrol enhances p53 acetylation and apoptosis in prostate cancer by inhibiting MTA1/NuRD complex , 2010, International journal of cancer.

[32]  R. Schüle,et al.  Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. , 2010, Carcinogenesis.

[33]  Kristen Jepsen,et al.  Deconstructing repression: evolving models of co-repressor action , 2010, Nature Reviews Genetics.

[34]  J. Workman,et al.  Deacetylase inhibitors dissociate the histone-targeting ING2 subunit from the Sin3 complex. , 2010, Chemistry & biology.

[35]  S. Baylin,et al.  Novel Oligoamine Analogues Inhibit Lysine-Specific Demethylase 1 and Induce Reexpression of Epigenetically Silenced Genes , 2009, Clinical Cancer Research.

[36]  J. Hagman,et al.  The Mi-2/NuRD complex: A critical epigenetic regulator of hematopoietic development, differentiation and cancer , 2009, Epigenetics.

[37]  C. Roberts,et al.  Oncogenesis caused by loss of the SNF5 tumor suppressor is dependent on activity of BRG1, the ATPase of the SWI/SNF chromatin remodeling complex. , 2009, Cancer research.

[38]  Dustin E. Schones,et al.  Genome-wide Mapping of HATs and HDACs Reveals Distinct Functions in Active and Inactive Genes , 2009, Cell.

[39]  Luyang Sun,et al.  LSD1 Is a Subunit of the NuRD Complex and Targets the Metastasis Programs in Breast Cancer , 2009, Cell.

[40]  R. Urrutia,et al.  Sin3: master scaffold and transcriptional corepressor. , 2009, Biochimica et biophysica acta.

[41]  A. Toland,et al.  Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatment. , 2009, Seminars in cancer biology.

[42]  Hanna Eskelinen,et al.  Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens. , 2009, Journal of molecular endocrinology.

[43]  Robert Brown,et al.  The promises and pitfalls of epigenetic therapies in solid tumours. , 2009, European journal of cancer.

[44]  D. Reisman,et al.  The SWI/SNF complex and cancer , 2009, Oncogene.

[45]  R. Versteeg,et al.  Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. , 2009, Cancer research.

[46]  I. Mills,et al.  Elevated NCOR1 disrupts a network of dietary-sensing nuclear receptors in bladder cancer cells. , 2009, Carcinogenesis.

[47]  G. Chinnadurai,et al.  The transcriptional corepressor CtBP: a foe of multiple tumor suppressors. , 2009, Cancer research.

[48]  Esther R. Loney,et al.  Genome Analysis Identifies the p15ink4b Tumor Suppressor as a Direct Target of the ZNF217/CoREST Complex , 2008, Molecular and Cellular Biology.

[49]  R. Lanz,et al.  Nuclear receptor coregulators and human disease. , 2008, Endocrine reviews.

[50]  D. Ish-Horowicz,et al.  The Groucho/TLE/Grg family of transcriptional co-repressors , 2008, Genome Biology.

[51]  Anthony M Flores,et al.  Corepressors of agonist-bound nuclear receptors. , 2007, Toxicology and applied pharmacology.

[52]  B. O’Malley,et al.  Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation. , 2007, Molecular cell.

[53]  J. Gaudet,et al.  Structural basis for recognition of SMRT/N-CoR by the MYND domain and its contribution to AML1/ETO's activity. , 2007, Cancer cell.

[54]  G. Buchanan,et al.  Androgen receptor coregulators and their involvement in the development and progression of prostate cancer , 2007, International journal of cancer.

[55]  Kamini Singh,et al.  MTA family of coregulators in nuclear receptor biology and pathology , 2007, Nuclear receptor signaling.

[56]  A. Baniahmad,et al.  Review Nuclear Receptor Signaling | The Open Access Journal of the Nuclear Receptor Signaling Atlas The coregulator Alien , 2022 .

[57]  R. Schüle,et al.  Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. , 2006, Cancer research.

[58]  C. Banwell,et al.  Epigenetic corruption of VDR signalling in malignancy. , 2006, Anticancer research.

[59]  C. Glass,et al.  Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. , 2006, Genes & development.

[60]  S. Minucci,et al.  Histone modification therapy of cancer. , 2010, Advances in genetics.

[61]  J. Wong,et al.  Nuclear receptor repression: regulatory mechanisms and physiological implications. , 2009, Progress in molecular biology and translational science.

[62]  J. Wong,et al.  Nuclear receptor repression: regulatory mechanisms and physiological implications. , 2009, Progress in molecular biology and translational science.

[63]  B. Lakowski,et al.  CoREST-like complexes regulate chromatin modification and neuronal gene expression , 2007, Journal of Molecular Neuroscience.

[64]  Karl Ekwall,et al.  Sin3: a flexible regulator of global gene expression and genome stability , 2004, Current Genetics.